Posted by Michael Wonder on 30 May 2017
Apogenix granted PRIME designation by European Medicines Agency for asunercept to treat glioblastoma
29 May 2017 - PRIME program designed to help patients benefit as early as possible from therapies that may significantly improve their quality of life.
Apogenix announced today that it has been awarded PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) for its lead product candidate, asunercept (APG101), for the treatment of glioblastoma.
The PRIME designation was based on the results of a Phase 2 trial (APG101_CD_002) of 86 adult patients with relapsed glioblastoma treated with asunercept.
